Market Insights
Companion diagnostic tests are used to identify suitable patients for administering specific drugs and monitoring the prognosis of drug effects on the disease. This concept of combining a drug with a diagnostic test is known as “predictive medicine” or “personalized medicine.” A companion diagnostic test has the ability to predict the risks of the disease and monitor its therapeutic response. The tests enable physicians to make decisions on the type of drugs and dosage administration and thereby reduce the mortality rates associated with diseases such as cancer and neurodegenerative disorders. The global companion diagnostics market is expected to witness significant growth during the forecast period, primarily due to the growing focus on cost-cutting in drug discovery and development. Asia Pacific is expected to grow at the highest rate during the forecast period due to increased adoption, technological advancements, and demand for personalized medicine. Vendors in the market are focusing on several strategies, such as licensing agreements, collaborations, and partnership activities, to develop highly specific molecular diagnostic tests to monitor or select target therapeutics for addressing the pathogenesis of major diseases.
The report titled “Companion Diagnostics Market: Growth, Share, Opportunities, and Competitive Analysis, 2016–2023” offers strategic insights into the overall companion diagnostics market, along with the market size and estimates for the duration of 2016 to 2023. The said research study covers an in-depth analysis of multiple market segments based on the type of indication, type of technology, and different geographical regions. The indication type segments studied for analyzing the overall companion diagnostics market are oncology, cardiovascular diseases, virology, and autoimmune diseases.
On the basis of technology, the companion diagnostics market has been segmented into a polymerase chain reaction, immunohistochemistry, in-situ hybridization, gene sequencing, and others. In order to help strategic decision-makers, the report also includes sections on the competitive profiling of the leading players in the companion diagnostics market, attractive investment propositions, Porter’s five forces model, and market positioning of key manufacturers. Other in-depth analysis provided in the report includes:
Geographically, the companion diagnostics market is studied for the following regional markets:
- North America
- Europe
- Germany
- France
- UK.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
The market size and forecast for these regional and country-level markets are presented in this study for the period 2013–2023. Market growth rates for the forecast period 2016–2023 are also included in this report, considering 2015 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global companion diagnostics market. Tools such as the market positioning of key players and an attractive investment proposition provide the reader with insights into the competitive scenario of the global companion diagnostics market.
This report concludes with a company profiles section that highlights major information about the key players engaged in the companion diagnostics market. In-depth competitive environment analysis and historical years (2013 and 2014) of market size data are also provided in the report.
Thus, the research study provides a holistic view of the global companion diagnostics market, offering market size and estimates for the period from 2016 to 2023, keeping in mind the above-mentioned factors.
Based on these indications, the global companion diagnostics market is segmented as follows:
- Oncology
- Breast Cancer
- Colorectal Cancer
- Gastric Cancer
- Lung Cancer
- Melanoma
- Others (neurology, prostate cancer, and ovarian cancer)
- Cardiovascular Diseases
- Infectious Diseases
- Autoimmune Diseases
Companion diagnostic tests are used to identify suitable patients for administering specific drugs and monitoring the prognosis of drug effects on the disease. This concept of combining a drug with a diagnostic test is known as “predictive medicine” or “personalized medicine.” A companion diagnostic test has the ability to predict the risks of the disease and monitor its therapeutic response. The tests enable physicians to make decisions on the type of drugs and dosage administration and thereby reduce the mortality rates associated with diseases such as cancer and neurodegenerative disorders. On the basis of indications, the global companion diagnostics market has been segmented as oncology, cardiovascular diseases, virology, and autoimmune diseases. The oncology segment has been further segmented on the basis of various cancers, such as breast cancer, colorectal cancer, gastric cancer, lung cancer, melanoma, and others.
The oncology segment held the largest market in the global companion diagnostics market by indication and is expected to be the highest-grossing segment through the forecast period. The major factors driving the oncology segment include the development of the majority of companion diagnostics for the detection of various cancer biomarkers. The key driver for this market is an increase in research and development of targeted drugs, which require a corresponding companion diagnostic. Moreover, the development of nanotechnology and nanomedicine and the advancements in drug delivery are driving the field of personalized medicine.
Based on the technology, the global market for companion diagnostics is segmented as follows:
- polymerase chain reaction
- Immunohistochemistry (IHC)
- In-Situ Hybridization Test (ISH)
- Gene Sequencing
- Others (monoclonal antibody testing and cellular immune testing)
Companion diagnostic tests are used to identify suitable patients for administering specific drugs and monitoring the prognosis of drug effects on the disease. This concept of combining a drug with a diagnostic test is known as “predictive medicine” or “personalized medicine.” A companion diagnostic test has the ability to predict the risks of the disease and monitor its therapeutic response. On the basis of technology, the companion diagnostics market has been segmented into a polymerase chain reaction, immunohistochemistry, in-situ hybridization, gene sequencing, and others.
The other segment includes tests such as monoclonal antibody testing and cellular immune testing. The polymerase chain reaction technique is the largest segment in the global companion diagnostics market. Factors such as high usage of the technique, cheaper rates, and efficient results have driven the polymerase chain reaction technique market. Gene sequencing is expected to exhibit the highest growth rate during the forecast period. The development of next-generation sequencing and third-generation sequencing has resulted in the efficient detection of biomarkers, thus gaining momentum in the companion diagnostic market in the future.
For the purpose of this study, the global companion diagnostics market is categorized as follows:
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa
The geographical segmentation of the global companion diagnostics market comprises North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. In the base year of 2015, North America accounted for the largest market in the global companion diagnostics industry. In North America, the US represented the largest market for companion diagnostic tests. This is mainly attributed to the growing demand for targeted therapeutics and the increase in the prevalence of the pathogenesis of various cancer ailments. In short, the demand for personalized medicines and diagnostics is driving the adoption of companion diagnostics.
However, stringent regulations are expected to limit the growth of the market and delay the launch of various products. Asia Pacific is expected to grow at the highest rate during the forecast period due to increased adoption, technological advancements, and demand for personalized medicine. Vendors in the market are focusing on several strategies, such as licensing agreements, collaborations, and partnership activities, to develop highly specific molecular diagnostic tests to monitor or select target therapeutics for addressing the pathogenesis of major diseases. Moreover, the increase in the prevalence of cancer and its associated disorders, the increase in healthcare expenditure, and the increase in awareness among the population all contribute to this trend. Thus, the APAC region is expected to adopt companion diagnostic tests at a rapid rate during the forecast period.
